Condition: Patients With Hematologic Disorders After Allogeneic Hematopoietic Stem Cell Transplantation · Hematologic Disorders · Sponsor: The General Hospital of Western Theater Command
This study is an investigator-initiated prospective, single-center, open-label clinical trial designed to evaluate the clinical efficacy and safety of Lusutrombopag in promoting platelet remodeling after allogeneic hematopoietic stem cell transplantation in patients with hematologic disorders.
This description comes directly from the study's public registry record.
Lei Ma · +8615680600612 · 408955783@qq.com
Always discuss trial participation with your own doctor first.
| The General Hospital of the People's Liberation Army | Chengdu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07483385